I am a healthcare professional in the UK
I am a patient or member of the public
ESOT 2025 Medical Symposium
ESOT 2025 Medical Symposium
Based primarily on data from Dobrer S, et al., this slide deck explores how cytomegalovirus (CMV) viral load kinetics influence patient and graft outcomes in kidney transplant recipients. CMV remains a persistent post-transplant challenge, even with prophylaxis and monitoring strategies. The data show that higher viral loads, prolonged infections, and recurrences are associated with poorer outcomes and increased graft loss. Also learn how factors such as D+/R– serostatus, older recipient age, and delayed graft function increase the risk of both initial and recurrent CMV infections.
/
You might be interested in
1 minute
download
This concise guide to LIVTENCITY® (maribavir) is designed for clarity and ease of use. It summarises key insights from the Phase 3 SOLSTICE trial, including efficacy outcomes, safety data, and practical dosing guidance.
article
6 minutes
A summary of the safety profile of LIVTENCITY, including adverse event data and tolerability findings from clinical studies.
article
5 minutes
Key efficacy outcomes from clinical trials evaluating LIVTENCITY in patients with post-transplant CMV, including virologic response and treatment comparisons.
article
3 minutes
CMV is one of the most common infections experienced by transplant recipients
article
4 minutes
An overview of the pivotal Phase 3 SOLSTICE trial, outlining the study design, patient population, and methodology that underpin the clinical evidence for LIVTENCITY.
